Clinical Trial

Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA

Study acronym: FusionVAC22_02
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The aim of this clinical trial is to evaluate the immunogenicity along with safety and toxicity as well as first efficacy of a DNAJB1-PRKACA fusion transcript-based peptide vaccine (Fusion-VAC-XS15) in patients with FL-HCC or other cancer entities carrying the DNAJB1-PRKACA fusion transcript as adjuvant treatment
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-01-17; most recent amendment 2026-02-09.
Status change: Not Yet Recruiting → Recruiting 2026-02-09
Trial Details
NCT Number NCT06789198
Lead Sponsor University Hospital Tuebingen
Conditions Fibrolamellar Hepatocellular Carcinoma (FLC)
Enrollment 20 participants
Start Date 2025-07-08
Primary Completion 2028-11 (estimated)
Study Completion 2028-11 (estimated)
Updated on ClinicalTrials.gov 2026-02-12